Key result
BI 456906 reduced placebo-corrected bodyweight by up to 12.37% after 16 weeks of treatment in healthy Japanese men with overweight/obesity.
Why the study?
Does BI 456906 reduce bodyweight and demonstrate safety in healthy Japanese men with overweight/obesity?
RCT (n=36)
Does BI 456906 reduce bodyweight and demonstrate safety in healthy Japanese men with overweight/obesity?
The dual GCGR/GLP-1R agonist BI 456906 demonstrated substantial weight loss and expected tolerability profiles in a Phase I study of Japanese men with overweight/obesity.
Answers are grounded in this paper and cite their sources.
May support weight management with BI 456906 in overweight Japanese men; extends RCT evidence to this population.
AIM: To report a Phase I study of subcutaneous glucagon receptor (GCGR)/glucagon-like peptide-1 receptor (GLP-1R) dual agonist BI 456906 versus placebo in healthy Japanese men with overweight/obesity. MATERIALS AND METHODS: . RESULTS: Thirty-six participants were treated (n = 9 per DG and placebo). Overall, 10 participants (37.0%) treated with BI 456906 withdrew from dose escalation due to adverse events (amylase increase, n = 1; decreased appetite, n = 9), and the proportion of participants was higher in DG 2 (n = 6, 66.7%) versus DGs 1 and 3 (both n = 2, 22.2%). No participants receiving placebo withdrew from dose escalation. BI 456906 exposure increased with dose and dose escalation in each DG. Treatment with BI 456906 decreased placebo-corrected bodyweight after 16 weeks (placebo +1.06%): DG 1, -5.57%; DG 2, -12.37%; DG 3, -9.62%. Paracetamol absorption decreased in Week 1 for DGs 2 and 3, indicating transient delayed gastric emptying. BI 456906 reduced plasma alanine and glucagon levels, indicating indirect target engagement at GCGRs and GLP-1Rs. Drug-related adverse events were reported for all participants receiving BI 456906 and four receiving placebo, the most frequent being decreased appetite (n = 24, 66.7%). CONCLUSIONS: BI 456906 showed no unexpected tolerability concerns and it reduced placebo-corrected bodyweight by up to 12.37% in Japanese men with overweight/obesity after 16 weeks of treatment.
No takes yet. Share an insight, caveat, or question.
Yazawa et al. (2023) conducted an RCT in overweight/obesity (n=36). BI 456906 vs. placebo was evaluated on placebo-corrected bodyweight change. BI 456906 reduced placebo-corrected bodyweight by up to 12.37% after 16 weeks of treatment in healthy Japanese men with overweight/obesity.
Synapse has enriched 10 related papers. Consider them for comparative context: